In the trial for NSCLC (which selected patients for HER2 overexpression), DESTINY-LUNG-01, no CAEs were reported at the recommended dose of 5.4 mg/kg [77] (see Table 1). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.